Claire Mazumdar, Director, Chief Executive Officer, on August 10, 2026, sold 10,000 shares in Bicara Therapeutics (BCAX) for $279,750. Following the Form 4 filing with the SEC, Mazumdar has control over a total of 362,152 common shares of the company, with 362,152 shares held directly.
SEC Filing:
Andrea Turner, Director, on August 10, 2026, sold 64,295 shares in Honest Company (HNST) for $338,073. Following the Form 4 filing with the SEC, Turner has control over a total of 252,405 common shares of the company, with 252,405 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1530979/000162828026055836/xslF345X05/wk-form4_1786485117.xml
Anthony Mathew Eisen, Director, on August 07, 2026, sold 18,000 shares in Block (XYZ) for $1,417,140. Following the Form 4 filing with the SEC, Eisen has control over a total of 1,542,672 Class A common shares of the company, with 1,542,672 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1512673/000162828026055837/xslF345X05/wk-form4_1786485228.xml
Christopher Peetz, Director, CEO, on August 10, 2026, sold 20,000 shares in Mirum Pharmaceuticals (MIRM) for $1,978,402. Following the Form 4 filing with the SEC, Peetz has control over a total of 381,809 common shares of the company, with 194,309 shares held directly and 187,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1759425/000161474026000012/xslF345X05/form4-08112026_090838.xml